These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15967119)

  • 1. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
    Hennig R; Ventura J; Segersvard R; Ward E; Ding XZ; Rao SM; Jovanovic BD; Iwamura T; Talamonti MS; Bell RH; Adrian TE
    Neoplasia; 2005 Apr; 7(4):417-25. PubMed ID: 15967119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of LY293111 in combination with gemcitabine in colonic cancer.
    Hennig R; Ding XZ; Tong WG; Witt RC; Jovanovic BD; Adrian TE
    Cancer Lett; 2004 Jul; 210(1):41-6. PubMed ID: 15172119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
    Sugisawa N; Miyake K; Higuchi T; Oshiro H; Zhang Z; Park JH; Kawaguchi K; Chawla SP; Bouvet M; Singh SR; Unno M; Hoffman RM
    Anticancer Res; 2019 Oct; 39(10):5339-5344. PubMed ID: 31570427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
    Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
    Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
    Jänne PA; Paz-Ares L; Oh Y; Eschbach C; Hirsh V; Enas N; Brail L; von Pawel J
    J Thorac Oncol; 2014 Jan; 9(1):126-31. PubMed ID: 24346102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
    Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
    Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
    Lee NC; Bouvet M; Nardin S; Jiang P; Baranov E; Rashidi B; Yang M; Wang X; Moossa AR; Hoffma RM
    Clin Exp Metastasis; 2000; 18(5):379-84. PubMed ID: 11467769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
    Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
    Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-pancreatic cancer agent, LY293111.
    Ding XZ; Talamonti MS; Bell RH; Adrian TE
    Anticancer Drugs; 2005 Jun; 16(5):467-73. PubMed ID: 15846111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
    Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
    Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
    BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.
    Haq M; Shafii A; Zervos EE; Rosemurgy AS
    Cancer Res; 2000 Jun; 60(12):3207-11. PubMed ID: 10866312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer.
    Al Shemaili J; Mensah-Brown E; Parekh K; Thomas SA; Attoub S; Hellman B; Nyberg F; Adem A; Collin P; Adrian TE
    Eur J Cancer; 2014 May; 50(7):1391-8. PubMed ID: 24462376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
    Katz MH; Takimoto S; Spivack D; Moossa AR; Hoffman RM; Bouvet M
    J Surg Res; 2003 Jul; 113(1):151-60. PubMed ID: 12943825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.